<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210216050373N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-11</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effectiveness of mindfulness-based cognitive therapy and Silva-based relaxation therapy on psychological capital, social anxiety and CD4 count in people with HIV</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of mindfulness-based cognitive therapy and Silva-based relaxation therapy on psychological capital, social anxiety and CD4 count in people with HIV</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-04-03</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68797</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: The block randomization method will be used for randomization. According to the three study groups, blocks of fixed size will be used in this research, with six patients in each block.
After generating the randomization sequence using the software (Random allocation software), the central randomization method will be used for allocation concealment.
To implement allocation concealment using the central randomization method, the generated randomization sequence is provided to the research department of the Iranian Research Center for HIV/AIDS (IRCHA).
After the patients' eligibility to enter the study and obtaining written informed consent from the patients, the researchers will call (phone) the relevant center (IRCHA) and ask about the allocation of the participants to the study groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>HIV-1 infection.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Mindfulness-based cognitive therapy group training: Before the training, a pre-test will be conducted. In this way, the research questionnaires (Lutans psychological capital and Lajarka social anxiety) will be completed. Also, 2 ml blood sampling will be done for the CD4 count. After the pre-test, cognitive therapy sessions based on mindfulness will be held twice a week for one month (each training session is 40 minutes). After two weeks of training, the "post-test" will be conducted like the pre-test. Intervention 2: Intervention group 2: Silva-based relaxation therapy: Group relaxation training in the Silva method: Before the implementation of the training, a pre-test will be performed. In this way, the research questionnaires (Lutans psychological capital and Lajerka social anxiety) will be completed. Also, 2 ml blood sampling will be done for the CD4 count. After the pre-test, the Silva relaxation sessions will be held twice a week for one month (each training session is 40 minutes). After two weeks of training, the "post-test" will be conducted like the pre-test. Intervention 3: Control group: they don't see any training. The pre-test will be conducted in such a way that the research questionnaires (Lutans psychological capital and Lajarka social anxiety) will be completed. Also, 2 ml of blood sampling will be done for the CD4 count. After the pre-test and after cognitive therapy training sessions based on mindfulness and Silva-based relaxation therapy were implemented for the intervention groups, after two weeks From the implementation of the trainings, the "post-test" will be implemented like the pre-test for the control group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The research results will be presented and published only in the form of reports and articles.

When:
The access period starts 6 months after the results are published.

To whom:
It will be available to researchers working in academic and scientific institutions.

Conditions:
Researchers for use in articles and reports, especially systematic review articles.

Where to obtain:
To receive the required documents or data, refer to the project manager, Dr. Seyed Ahmad Seyed Alinghi, at the Iranian Research Center for HIV/AIDS. Phone number: 00982166581583 Email: s.a.alinaghi@gmail.com Address: Iranian Research Center for HIV/AIDS, behind the Infectious Diseases Building, Imam Khomeini Hospital Complex, end of Keshavarz Boulevard, Tehran.

How to obtain:
After making the call(Phone, meet, Email) and providing the necessary documents(Written request), the documents or data files will reach the applicant.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Pegah Mirzapour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital Complex, Tohid Square, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733141</zip>
        <telephone>+98 919 436 5685</telephone>
        <email>pegah.mirzapour@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>SeyedAhmad SeyedAlinaghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital Complex, Tohid Square, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733141</zip>
        <telephone>+98 912 644 8153</telephone>
        <email>s.a.alinaghi@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>HIV infection
Having full consent to cooperate
Absence of acute disorders in the field of psychology and psychiatry
Not using drugs; Psychiatric drugs
Being literate in reading and writing</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Refusing to cooperate with the researcher
Absence of more than two sessions in therapy training</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B20</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Human immunodeficiency virus [HIV] disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Mindfulness-based cognitive therapy group training: Before the training, a pre-test will be conducted. In this way, the research questionnaires (Lutans psychological capital and Lajarka social anxiety) will be completed. Also, 2 ml blood sampling will be done for the CD4 count. After the pre-test, cognitive therapy sessions based on mindfulness will be held twice a week for one month (each training session is 40 minutes). After two weeks of training, the "post-test" will be conducted like the pre-test.</i_keyword>
      <i_keyword>Intervention group 2: Silva-based relaxation therapy: Group relaxation training in the Silva method: Before the implementation of the training, a pre-test will be performed. In this way, the research questionnaires (Lutans psychological capital and Lajerka social anxiety) will be completed. Also, 2 ml blood sampling will be done for the CD4 count. After the pre-test, the Silva relaxation sessions will be held twice a week for one month (each training session is 40 minutes). After two weeks of training, the "post-test" will be conducted like the pre-test.</i_keyword>
      <i_keyword>Control group: they don't see any training. The pre-test will be conducted in such a way that the research questionnaires (Lutans psychological capital and Lajarka social anxiety) will be completed. Also, 2 ml of blood sampling will be done for the CD4 count. After the pre-test and after cognitive therapy training sessions based on mindfulness and Silva-based relaxation therapy were implemented for the intervention groups, after two weeks From the implementation of the trainings, the "post-test" will be implemented like the pre-test for the control group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Conscious attention in the present with acceptance and non-judgment. Timepoint: 1- At the beginning of the study (before the start of the intervention) 2- 14 days after the last educational intervention. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Awareness and alertness based on care and attention. Timepoint: 1- At the beginning of the study (before the start of the intervention) 2- 14 days after the last educational intervention. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Increase mental strength and concentration. Timepoint: 1- At the beginning of the study (before the start of the intervention) 2- 14 days after the last educational intervention. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>CD4 count. Timepoint: 1- At the beginning of the study (before the start of the intervention) 2- 14 days after the last educational intervention. Method of measurement: Blood test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice-Chancellors of Research and Technology of Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-02-14</approval_date>
        <contact_name>Ethics committee of Imam khomeini Hospital Complex- Tehran University of Medical Sciences</contact_name>
        <contact_address>Imam Khomeini Hospital Complex, Tohid Square, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
